Although PSA remains the most established and widely used biomarker for prostate cancer, other molecular markers such as Prostate Health Index (PHI), 4Kscore, and PCA3 are being increasingly utilized to improve diagnostic specificity and risk stratification [1,2,3]. This evidence concerns the gene KLK3 and prostate carcinoma.